Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03599063 · ClinicalTrials.gov registry record · Phase 1
Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT03599063 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 63 participants.
The verdict
NCT03599063, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
Interventions
- OTHER Placebo
- BIOLOGICAL PF-06946860
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2019-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03599063
The ClinicalTrials.gov registry entry for NCT03599063 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03599063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03599063 about?
NCT03599063 is a clinical study titled "Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PF-06946860 in healthy adult subjects following single ascending doses This is the first clinical study of PF-06946860.
What is the current status of trial NCT03599063?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2018-07-30. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT03599063?
The interventions under investigation include: Placebo (OTHER), PF-06946860 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03599063?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.